2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
13
Head & Neck
9
Thoracic
6
Lymphoid
4
Other solid neoplasm
2
Endocrine
2
Breast
2
Sarcoma
1
Other neoplasm
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Osteosarcoma
1
Interventions
Radiotherapy
220
Doxorubicin
210
Cyclophosphamide
210
Temozolomide
182
Ifosfamide
121
Filgrastim
111
Imatinib Mesylate
104
Etoposide
101
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
80
Irinotecan
79
pembrolizumab
75
Radiation
69
Carboplatin
65
Methotrexate
62
pazopanib
61
Nivolumab
58
Cisplatin
58
fludarabine phosphate
57
Peripheral Blood Stem Cell Transplantation
57
Surgical Procedures, Operative
56
Specimen Handling
56
Trabectedin
52
Docetaxel
50
Biopsy
50
Busulfan
49
Melphalan
46
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
penpulimab
×
Sarcoma
×
Clear all
NCT06114225
2023-11-02
PROMIS
Ruijin Hospital
Phase 2
Recruiting
43 enrolled